Retinal vein occlusion associated with antithrombin deficiency secondary to a novel G9840C missense mutation

Archives of Ophthalmology

Volumn 124, Issue 8, 2006, Pages 1165-1169

  Kuhli, Claudia ^a   Jochmans, Kristin ^b   Scharrer, Inge ^a   Lüchtenberg, Marc ^a   Hattenbach, Lars Olof ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ASPARTIC ACID; CYTOSINE; GUANOSINE; HISTIDINE;

ADULT; ANAMNESIS; ANTITHROMBIN DEFICIENCY; ARTICLE; CASE REPORT; CLINICAL FEATURE; CODON; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DETERMINATION; DOSE RESPONSE; EXON; GENETIC ANALYSIS; GLAUCOMA; HUMAN; LABORATORY TEST; MALE; MISSENSE MUTATION; OPHTHALMOSCOPY; PRIORITY JOURNAL; RETINA VEIN OCCLUSION; RISK FACTOR; SCREENING; THROMBOPHILIA;

ADULT; DNA MUTATIONAL ANALYSIS; FIBRIN; HUMANS; IMMUNOELECTROPHORESIS; MALE; MUTATION, MISSENSE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RETINAL VEIN OCCLUSION; SEQUENCE ANALYSIS, DNA;

EID: 33747155571     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.124.8.1165     Document Type: Article

References (37)

1. Greiner K, Hafner G, Dick B, Dirk PE, Prellwitz W, Pfeiffer N. Retinal vascular occlusion and deficiency in the protein C pathway. Am J Ophthalmol. 1999;128:69-74.
2. Incorvaia C, Lamberti G, Parmeggiani F, et al. Idiopathic central retinal vein occlusion in a thrombophilic patient with the heterozygous 20210 G/A prothrombin genotype. Am J Ophthalmol. 1999;128:247-248.
3. Hattenbach LO, Klais C, Scharrer I. Heparin cofactor II deficiency in central retinal vein occlusion. Acta Ophthalmol Scand. 1998;76:758-759.
4. Kuhli C, Hattenbach LO, Scharrer I, Koch F, Ohrloff C. High prevalence of resistance to APC in young patients with retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2002;240:163-168.
5. Kuhli C, Scharrer I, Koch F, Hattenbach LO. Recurrent retinal vein occlusion in a patient with increased plasma levels of histidine-rich glycoprotein. Am J Ophthalmol. 2003;135:232-234.
6. Kuhli C, Scharrer I, Koch F, Ohrloff C, Hattenbach LO. Factor XII deficiency: a thrombophilic risk factor for retinal vein occlusion. Am J Ophthalmol. 2004;137:459-464.
7. Pratt CW, Church FC. Antithrombin: structure and function. Semin Hematol. 1991;28:3-9.
8. Bock SC, Wion KL, Vehar GA, Lawn RM. Cloning and expression of the cDNA for human antithrombin III gene. Nucleic Acids Res. 1982;10:8113-8125.
9. Bock SC, Harris JF, Balazs I, Trent JM. Assignment of the human antithrombin III structural gene to chromosome 1q23-25. Cytogenet Cell Genet. 1985;39:67-69.
10. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh. 1965;13:516-530.
11. Lane DA, Ireland H, Olds RJ, Thein SL, Perry DJ, Aiach M. Antithrombin III: a database of mutations. Thromb Haemost. 1991;66:657-661.
12. Odegard OR, Abildgaard U. Antithrombin III: critical review of assay methods: significance of variations in health and disease. Haemostasis. 1978;7:127-134.
13. Conard J, Horellou MH, Samama M. Incidence of thromboembolism in association with congenital disorders in coagulation and fibrinolysis. Acta Chir Scand Suppl. 1988;543:15-25.
14. Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases [letter]. Thromb Haemost. 1987;58:1094.
15. Saiki RK, Gelfand DH, Stoffel S, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 1988;239:487-491.
16. Laurell CB. Elektroimmuno assay. Scand J Clin Lab Invest Suppl. 1972;124:21-37.
17. Sas G, Pepper D, Cash J. Investigations on antithrombin III in normal plasma and serum. Br J Haematol. 1975;30:265-272.
18. Kunkel LM, Smith KD, Boyer SD, et al. Analysis of human Y-chromosome-specific reiterated DNA in chromosome variants. Proc Natl Acad Sci U S A. 1977;74:1245-1249.
19. Olds RJ, Lane DA, Finazzi G, Barbui T, Thein SL. A frameshift mutation leading to type 1 antithrombin deficiency and thrombosis. Blood. 1990;76:2182-2186.
20. Vidaud D, Emmerich J, Sirieix ME, Sié P, Alhenc-Gelas M, Aiach M. Molecular basis for antithrombin III type I deficiency: three novel mutations located in exon IV. Blood. 1991;78:2305-2309.
21. Jochmans K, Lissens W, Vervoort R, Peeters S, De Waele M, Liebaers I. Antithrombin-Gly 424 Arg: a novel point mutation responsible for type I antithrombin deficiency and neonatal thrombosis. Blood. 1994;83:146-151.
22. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci U S A. 1989;86:2766-2770.
23. Anderson RD, Bao CY, Minnick DT, Veigl M, Sedwick WD. Optimization of Double-Stranded DNA Sequencing for Polymerase Chain Reaction Products. Cleveland, Ohio: US Biochemical; 1992: comments 19:39.
24. Maniatis T, Fritsch EF, Sambrook J. Molecular Cloning. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1982.
25. Lane DA, Olds RJ, Boisclair M, et al; Thrombin and Its Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Antithrombin III mutation database: first update. Thromb Haemost. 1993;70:361-369.
26. Lane DA, Olds RJ, Thein SL. Antithrombin III: summary of first database update. Nucleic Acids Res. 1994;22:3556-3559.
27. Olds RJ, Lane DL, Chawdhury V, De Stefano V, Leone G, Thein SL. Complete nucleotide sequence of antithrombin gene: evidence for homologous recombination causing thrombophilia. Biochemistry. 1993;32:4216-4224.
28. Dahlbäck B, Carlson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: a prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993;90:1004-1008.
29. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
30. 506). Arterioscler Thromb Vasc Biol. 1997;17:1662-1666.
31. Heijboer H, Brandjes DP, Buller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med. 1990;323:1512-1516.
32. Tabernero MD, Tomas JF, Alberca I, et al. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol. 1991;36:249-254.
33. Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem. 1973;248:6490-6505.
34. Jochmans K, Lissens W, Yin T, et al. Molecular basis for the type 1 antithrombin deficiency: identification of two novel point mutations and evidence for a de novo splice site mutation. Blood. 1994;84:3742-3748.
35. Olds RJ, Lane DA, Caso R, et al. Antithrombin III Budapest: a single amino acid substitution (429Pro to Leu) in a region highly conserved in the serpin family. Blood. 1992;79:1206-1212.
36. Gandrille S, Vidaud D, Emmerich J, et al. Molecular basis for hereditary antithrombin III quantitative deficiencies: a stop codon in exon IIIa and a frameshift in exon VI. Br J Haematol. 1991;78:414-420.
37. Olds RJ, Lane DA, Ireland H, et al. Novel point mutations leading to type 1 antithrombin deficiency and thrombosis. Br J Haematol. 1991;78:408-413.